XOMA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:03):

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health...

Stats
Šios dienos apimtis	2 496.00
Vidutinė apimtis	18 172.00
Rinkos kapitalizacija	297.35M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $-0.640 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.33
ATR14	$0.324 (1.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Hughes Owen	Buy	275 000	Performance Stock Units
2023-10-03	Sitko Bradley	Buy	250	Common Stock
2023-10-02	Sitko Bradley	Buy	1 500	Common Stock
2023-10-02	Hughes Owen	Buy	1 000	Common Stock
2023-09-26	Hughes Owen	Buy	2 499	Common Stock

INSIDER POWER
96.99
Last 95 transactions
Buy: 1 668 857 \| Sell: 210 377

XOMA Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

XOMA Corp Finansinės ataskaitos

Annual	2023
Pajamos:	$4.76M
Bruto pelnas:	$3.86M (81.08 %)
EPS:	$-3.56

FY	2023
Pajamos:	$4.76M
Bruto pelnas:	$3.86M (81.08 %)
EPS:	$-3.56

FY	2022
Pajamos:	$6.03M
Bruto pelnas:	$5.93M (98.39 %)
EPS:	$-1.500

FY	2021
Pajamos:	$38.16M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0.690

Financial Reports:

No articles found.

XOMA Corp

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.